Video

Dr. Markman on PCP Awareness of Long-Term Side Effects

Dr. Maurie Markman, Cancer Treatment Centers of America, on Primary Care Physician Awareness of Long-Term Chemotherapy Side Effects

Maurie Markman, MD, senior vice president for Clinical Affairs, National Director for Medical Oncology, Cancer Treatment Centers of America, Eastern Regional Medical Center, discusses a large survey that will be presented at the 2012 ASCO Annual Conference, focusing on primary care provider (PCPs) awareness of long-term side effects (LEs) in cancer survivors.

The survey demonstrated that many PCPs are not familiar with the recognized LEs of common chemotherapy drugs for colorectal and breast cancers. Markman notes that as the population of cancer survivors continues to grow, PCPs will become increasingly responsible for follow-up care.

The survey looked at a nationally representative sample of 1072 PCPs and 1130 oncologists and found that nearly all oncologists (95.3%) in the survey were able to identify LEs. In contrast, only half of PCPs recognized cardiac dysfunction as a result of Adriamycin and just over 21% connected peripheral neuropathy with oxaliplatin and Taxol.

The expressed lack of PCP knowledge of LEs is a recognizable defect, Markman notes. The survey demonstrates that additional education is necessary, in order for PCPs to be able to adequately identify LEs in cancer survivors.

<<<

View more from the 2012 ASCO Conference

Related Videos
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School